Candel Therapeutics to Present at September Investor Conferences
NEEDHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in analyst-led fireside discussions and one-on-one meetings at upcoming investor conferences in September 2026.
Covered in this story
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.